Spotlight Stories
-
What Will The Incoming Trump Administration Mean For Drug Patents?
11/21/2024
Megan Chacon, a principal at Fish & Richardson and a member of the firm’s life sciences industry team, answers questions about what a second Trump administration could mean for biopharmaceutical IP and drug patents.
-
Annovis Bio: Against The Grain In Alzheimer's Disease
10/1/2024
From biochemist to executive supplier to angel investor to company founder and CEO, Maria Maccecchini, Ph.D.’s independent-minded approach to neurodegenerative disease could shake up the treatment landscape.
-
Cash Needed For Phase 3 Celiac Drug Development
6/28/2024
Industry veteran James Sapirstein, CEO of Entero Therapeutics, discusses the company's lead candidate, a treatment for celiac disease, and makes the case for investors and Big Pharma to step up and help bring it across the finish line.
-
Partnering To Address 'Huge' Opportunities In Women's Health
6/14/2024
Nonprofit research foundations can offer scientific expertise and support for biopharmaceutical drug development and clinical programs, helping companies improve new and existing drugs for women.
-
Reviva Pharma's Novel Funding Approach In Schizophrenia
4/25/2024
Reviva Pharma CEO Laxminarayan Bhat, Ph.D. found a novel way to build an investor base for his company during a time when Big Pharma was exiting complicated CNS diseases. Now, Reviva has a late-stage schizophrenia candidate just as CNS is back in vogue.
-
A View From The Co-Chair Of Israel's Biopharma Industry Trade Organization
3/28/2024
Yaacov Michlin, co-chair of the IATI, discusses the advantages and disadvantages of Israel’s biopharma industry, the industry impact of the war in Gaza, and the difference between the U.S. and Israel regarding Chinese CDMOs.
-
NORD Expands Advocacy And Support For Rare Disease Patients, And Industry
2/29/2024
NORD's president and CEO, Peter Saltonstall, offers details on the organization's current activities and ongoing work with biopharmaceutical companies developing rare disease drugs.
-
No Playbook For Leqembi: Eisai's Long Game In Alzheimer's Disease
2/16/2024
Paul Hawthorne, Eisai's EVP, purpose and chief business officer, offers insight into building a market for Leqembi, Eisai's pricing and commercial strategy, and the challenges and opportunities in Alzheimer's disease.
-
Dynavax's Evolving Business Model
2/9/2024
Dynavax found a new revenue stream during COVID, and a way to grow market share in the absence of a market. Ryan Spencer describes the ups and downs, and his own journey to CEO role.
-
Empress Builds Base for Small-Molecule Innovation
2/1/2024
Empress, launched by Flagship Pioneering, aims to harness AI and evolutionary biology to design the next generation of small molecule therapies.